卫光生物(002880.SZ)拟合资设立项目公司 建设深圳市细胞与基因治疗市场化公共服务平台

Core Viewpoint - The company is establishing a joint venture named Shenzhen Xihe Life Technology Co., Ltd. to create a public service platform for cell and gene therapy (CGT) in Shenzhen, aiming to enhance market standardization and development [1][2] Group 1: Joint Venture Details - The initial registered capital of the joint venture is 100 million yuan, with the company contributing 40 million yuan, representing a 40% equity stake [1] - The joint venture will focus on building a CGT public service platform that serves both domestic and global markets, emphasizing the entire industry chain from plasmid to viral vectors and cell drugs [1] Group 2: Strategic Importance - This initiative is a strategic move for the company to extend its core advantages from the blood products sector into the cutting-edge biopharmaceutical field [2] - The project aims to enhance the company's strategic layout in the biopharmaceutical sector, cultivate new business growth points, and strengthen its competitive edge [2] - It serves as a crucial step for the company to achieve strategic upgrades and promote high-quality development [2]